PE20030950A1 - Comprimido masticable con sabor agradable - Google Patents
Comprimido masticable con sabor agradableInfo
- Publication number
- PE20030950A1 PE20030950A1 PE2003000337A PE2003000337A PE20030950A1 PE 20030950 A1 PE20030950 A1 PE 20030950A1 PE 2003000337 A PE2003000337 A PE 2003000337A PE 2003000337 A PE2003000337 A PE 2003000337A PE 20030950 A1 PE20030950 A1 PE 20030950A1
- Authority
- PE
- Peru
- Prior art keywords
- flavor
- sacrose
- cyclodextrin
- cetirizine
- pleasant flavor
- Prior art date
Links
- 239000000796 flavoring agent Substances 0.000 title abstract 3
- 235000019634 flavors Nutrition 0.000 title abstract 3
- 239000007910 chewable tablet Substances 0.000 title 1
- 229940068682 chewable tablet Drugs 0.000 title 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 229960001803 cetirizine Drugs 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- AMWZYEYIOPBLEO-UHFFFAOYSA-N 2-[2-[4-[(2-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 AMWZYEYIOPBLEO-UHFFFAOYSA-N 0.000 abstract 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 235000019658 bitter taste Nutrition 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 239000008371 vanilla flavor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37008602P | 2002-04-04 | 2002-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030950A1 true PE20030950A1 (es) | 2003-11-12 |
Family
ID=28792024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000337A PE20030950A1 (es) | 2002-04-04 | 2003-04-02 | Comprimido masticable con sabor agradable |
Country Status (23)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2354688T3 (es) * | 2002-01-15 | 2011-03-17 | Ucb Farchim S.A. | Formulaciones para la administración oral de compuestos activos. |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| EP1758856A2 (en) | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
| CA2574602A1 (en) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| PL2486942T3 (pl) | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| WO2007144902A1 (en) * | 2006-06-12 | 2007-12-21 | Jubliant Organosys Limited | Chewable bilayer tablet formulation |
| EP2178521B1 (en) * | 2007-07-11 | 2014-01-15 | Fertin Pharma A/S | Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| WO2009006892A1 (en) * | 2007-07-11 | 2009-01-15 | Fertin Pharma A/S | Stable medicated chewing gum comprising antioxidant |
| EP2178522A1 (en) * | 2007-07-11 | 2010-04-28 | Fertin Pharma A/S | Compressed chewing gum tablet comprising taste-masking agent |
| CL2008003230A1 (es) * | 2007-11-01 | 2009-11-27 | Sanofi Aventis Healthcare Pty Ltd | Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta. |
| CN102711739B (zh) | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | 双层片剂 |
| WO2011110939A2 (en) | 2010-03-11 | 2011-09-15 | Rubicon Research Private Limited | Pharmaceutical compositions of substituted benzhydrylpiperazines |
| WO2013129436A1 (ja) * | 2012-02-29 | 2013-09-06 | 武田薬品工業株式会社 | 経口剤 |
| PL2861236T3 (pl) | 2012-06-15 | 2020-03-31 | Pharmathen S.A. | Kompozycja farmaceutyczna zawierająca polimer wiążący fosforany |
| CN102716099B (zh) * | 2012-07-05 | 2013-10-09 | 湖南千金湘江药业股份有限公司 | 盐酸左西替利嗪咀嚼片及其制备方法 |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| JP2016094364A (ja) * | 2014-11-14 | 2016-05-26 | ニプロ株式会社 | 安定化および苦味抑制された口腔内崩壊製剤 |
| EP3061501A1 (en) | 2015-02-27 | 2016-08-31 | Rottapharm Ltd. | Composition for the treatment of acne |
| EP3117825A1 (en) | 2015-07-16 | 2017-01-18 | Rottapharm S.p.A. | Oral formulation comprising berberine and morus alba extract |
| JP2019001730A (ja) * | 2017-06-13 | 2019-01-10 | 武田テバファーマ株式会社 | 安定な経口医薬組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558600A (en) | 1967-07-28 | 1971-01-26 | Abbott Lab | Alkyl sulfate salts of 1-(p-chlorobenzhydryl)-4-methylhomopiperazines |
| NO155805C (no) | 1981-02-06 | 1987-06-10 | Ucb Sa | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. |
| US4650663A (en) | 1983-07-20 | 1987-03-17 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives |
| US4792448A (en) | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
| IL91398A (en) | 1988-08-30 | 1994-05-30 | Pfizer | Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane |
| DE9190107U1 (de) | 1990-08-07 | 1993-12-16 | Pfizer Inc., New York, N.Y. | Abgabe-Vorrichtung mit durch Grenzflächen-Polymerisation erhaltenen Membranen |
| CA2146637C (en) | 1992-10-09 | 2001-02-13 | James Grigg Upson | Pharmaceutical compositions and methods for treating cold symptoms |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US6027746A (en) * | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
| BE1011251A3 (fr) * | 1997-07-03 | 1999-06-01 | Ucb Sa | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine. |
| DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
| US6270790B1 (en) | 1998-08-18 | 2001-08-07 | Mxneil-Ppc, Inc. | Soft, convex shaped chewable tablets having reduced friability |
| US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| ES2354688T3 (es) * | 2002-01-15 | 2011-03-17 | Ucb Farchim S.A. | Formulaciones para la administración oral de compuestos activos. |
-
2003
- 2003-03-26 ES ES03745693T patent/ES2298540T3/es not_active Expired - Lifetime
- 2003-03-26 CN CNB038070448A patent/CN100335041C/zh not_active Expired - Fee Related
- 2003-03-26 EP EP03745693A patent/EP1494654B1/en not_active Expired - Lifetime
- 2003-03-26 WO PCT/IB2003/001130 patent/WO2003084511A1/en not_active Ceased
- 2003-03-26 DE DE60319685T patent/DE60319685T2/de not_active Expired - Lifetime
- 2003-03-26 AT AT03745693T patent/ATE388693T1/de not_active IP Right Cessation
- 2003-03-26 PL PL03372904A patent/PL372904A1/xx not_active Application Discontinuation
- 2003-03-26 CA CA002481025A patent/CA2481025A1/en not_active Abandoned
- 2003-03-26 IL IL16410603A patent/IL164106A0/xx unknown
- 2003-03-26 BR BR0308927-4A patent/BR0308927A/pt not_active IP Right Cessation
- 2003-03-26 KR KR10-2004-7015586A patent/KR20040098036A/ko not_active Ceased
- 2003-03-26 RU RU2004129573/15A patent/RU2004129573A/ru not_active Application Discontinuation
- 2003-03-26 MX MXPA04009617A patent/MXPA04009617A/es active IP Right Grant
- 2003-03-26 JP JP2003581751A patent/JP2005526104A/ja active Pending
- 2003-04-01 US US10/404,964 patent/US7482022B2/en not_active Expired - Fee Related
- 2003-04-02 TW TW092107552A patent/TW200401651A/zh unknown
- 2003-04-02 PE PE2003000337A patent/PE20030950A1/es not_active Application Discontinuation
- 2003-04-02 UY UY27746A patent/UY27746A1/es not_active Application Discontinuation
- 2003-04-03 AR ARP030101167A patent/AR039242A1/es unknown
- 2003-04-03 HN HN2003000112A patent/HN2003000112A/es unknown
- 2003-04-04 PA PA20038570601A patent/PA8570601A1/es unknown
-
2004
- 2004-09-17 ZA ZA200407537A patent/ZA200407537B/en unknown
- 2004-11-03 NO NO20044774A patent/NO20044774L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2298540T3 (es) | 2008-05-16 |
| EP1494654B1 (en) | 2008-03-12 |
| BR0308927A (pt) | 2005-01-04 |
| RU2004129573A (ru) | 2005-04-10 |
| ATE388693T1 (de) | 2008-03-15 |
| UY27746A1 (es) | 2003-10-31 |
| CN100335041C (zh) | 2007-09-05 |
| MXPA04009617A (es) | 2005-01-11 |
| ZA200407537B (en) | 2006-06-28 |
| WO2003084511A1 (en) | 2003-10-16 |
| AU2003209953A1 (en) | 2003-10-20 |
| DE60319685D1 (de) | 2008-04-24 |
| US7482022B2 (en) | 2009-01-27 |
| IL164106A0 (en) | 2005-12-18 |
| PL372904A1 (en) | 2005-08-08 |
| EP1494654A1 (en) | 2005-01-12 |
| CN1642531A (zh) | 2005-07-20 |
| PA8570601A1 (es) | 2003-12-10 |
| NO20044774L (no) | 2004-11-03 |
| US20030215503A1 (en) | 2003-11-20 |
| JP2005526104A (ja) | 2005-09-02 |
| AR039242A1 (es) | 2005-02-16 |
| CA2481025A1 (en) | 2003-10-16 |
| TW200401651A (en) | 2004-02-01 |
| DE60319685T2 (de) | 2009-03-26 |
| HN2003000112A (es) | 2004-05-05 |
| KR20040098036A (ko) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2377839T3 (es) | Preparación oral que compende pioglitazona | |
| HUP0102676A2 (hu) | Szilárd, gyorsan széteső cetirizint tartalmazó gyógyszerkészítmények | |
| EP1863443B1 (en) | Rapidly disintegrating dosage form comprising magnesium carbonate heavy | |
| BRPI0517891A (pt) | composições compreendendo azelastina e métodos de uso das mesmas | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| NO20041086L (no) | Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem | |
| CA2447924A1 (en) | Olopatadine formulations for topical administration | |
| MY141243A (en) | Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
| HU228927B1 (en) | Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis, or conjunctivitis | |
| WO2004066910A3 (en) | Controlled release modifying complex and pharmaceutical compositions thereof | |
| BR9810320A (pt) | Composição farmacêutica sólida, contendo derivados de benzofurano | |
| RU2004129573A (ru) | Жевательная таблетка с приятным вкусом | |
| BR0208421A (pt) | Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes | |
| JPWO2016076280A1 (ja) | 光に対して不安定な薬物を含有する多層錠剤 | |
| NO20060991L (no) | Feksofenadinsammensetning og fremgangsmate til fremstilling | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| ECSP044979A (es) | Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña | |
| BR0116060A (pt) | Composição farmacêutica de dronedarona para administração parenteral | |
| CO5261595A1 (es) | Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium | |
| ES2793724T3 (es) | Formulación pediátrica | |
| US20050075403A1 (en) | Ambroxol for the treatment of inflammation in the pharynx | |
| WO2005011604A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |